Immune microenvironment of Langerhans cell histiocytosis: from immune suppression to targeted therapy
10.3760/cma.j.cn121090-20241030-00425
- VernacularTitle:朗格汉斯细胞组织细胞增生症的免疫微环境：从免疫抑制到靶向治疗
- Author:
Zhengzheng LIU
1
;
Xinxin CAO
Author Information
1. 国家癌症中心、国家肿瘤临床医学研究中心、中国医学科学院北京协和医学院肿瘤医院内科，北京 100021
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2025;46(7):673-678
- CountryChina
- Language:Chinese
-
Abstract:
Langerhans cell histiocytosis (LCH) is a rare hematologic disorder characterized by the clonal proliferation of neoplastic dendritic cells (DCs), exhibiting both immature and senescent immune phenotypes. The immunosuppressive microenvironment in LCH includes an increased proportion of regulatory T (Treg) cells with inhibitory functions, as well as exhausted CD8 + T cells and myeloid-derived suppressor cells, which collectively exacerbate immunosuppression and facilitate the immune evasion of tumor DCs. Current therapeutic approaches for LCH are limited by the challenges of relapse and drug resistance. However, emerging strategies that target the senescent phenotype of neoplastic DCs, inhibit Treg cell activity, and reverse T cell exhaustion through immune checkpoint blockade offer promising avenues for the treatment of LCH.
